Study of Abemaciclib for Patients with RBPositive Triple Negative Metastatic Breast Cancer

>> DOWNLOAD LINK 🎞️ #1 <<

>> DOWNLOAD LINK 🎞️ #2 <<

>> COPY / PASTE LINK PLEASE 🎵 MP3 <<

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=jHQOmdywJcE

Shom Goel, MD, PhD, provides an overview of a study at Dana-Farber Cancer Institute to evaluate the response to abemaciclib (Verzenio™) in patients with RB-positive, triple negative metastatic breast cancer. • Dana-Farber Cancer Institute offers the largest number of clinical trials for metastatic breast cancer in the country through our Embrace program. For more information about clinical trials for breast cancer, please visit http://dfcibreastclinicaltrials.org/. • For more information about Embrace, please visit https://www.dana-farber.org/metastati....

#############################